Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a prospective phase II study to assess the efficacy and toxicity of HSV-tk+
valacyclovir gene therapy in combination with androgen deprivation therapy, brachytherapy,
external beam radiotherapy, and prostatectomy in previously untreated high-risk prostate
cancer.
Phase:
Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute The Methodist Hospital System